Demonstration Formulary
6 Endocrine system
06-06-02 Bisphosphonates
| Alendronic acid Binosto® |
|
Third Choice
|
 MHRA: Bisphosphonates: atypical femoral fractures NICE TA464:Bisphosphonates for treating osteoporosis |
|
| Alendronic Acid |
|
Non Formulary
|
Removed from formulary in Decemeber 2016, replaced by effervescent tablets |
|
| Risedronate Sodium Actonel® |
|
Non Formulary
|
Actonel - Black RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL - Black RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL / Actonel Combi - Black
|
|
UKMI Q&A: Can oral bisphosphonates be given to people with renal impairment to treat osteoporosis? MHRA: Bisphosphonates: atypical femoral fractures NICE TA464: Bisphosphonates for treating osteoporosis TA 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) |
|
|
Links
- DVLA guidance
- ESCA: Denosumab (Prolia)-Sandwell only
- ESCA: Ibandronic acid 50mg-Sandwell only
- ESCA: Sodium clodronate-Sandwell only
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA; Bisphosphonates: atypical femoral fractures
- NICE Guidance on prescribing
- NICE NG28: Type 2 diabetes in adults: management
- NICE TA 791: Romosozumab for treating severe osteoporosis
- NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA160: Osteoporosis - primary prevention- NICE TA160: Osteoporosis - Primary Prevention
- NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate)
- NICE TA161: Osteoporosis - secondary prevention (including Teriparatide)
- NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
- NICE TA265: Bone metastases from solid tumours - denosumab: guidance (TA265 )
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA464:Bisphosphonates for treating osteoporosis
- NOGG Osteoporosis - information for patients
- NOGG Osteoporosis Clinical Guideline Executive Summary
- NOGG Pocket Guide for Heathcare Professionals - Osteoporosis
- TA 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
- UKMI Q&A: Can oral bisphosphonates be given to people with renal impairment to treat osteoporosis?
UKMI Q&A: Proton pump inhibitor interaction with bisphosphonates? -